-
Mashup Score: 0
Steven Nissen, MD, spoke with Cardiovascular Business at ACC.23 about the late-breaking CLEAR Outcomes trial.
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint | Esperion Therapeutics, Inc. - 1 year(s) ago
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Source: Esperion Therapeutics Inc.Categories: Expert Picks, Latest HeadlinesTweet-
CLEAR Outcomes trial meets its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day #NEXLETOL compared to placebo. https://t.co/eTqYjdB10J
-
-
Mashup Score: 07 new FDA-approved drugs in 2020 | MDLinx - 4 year(s) ago
COVID-19 hasn’t slowed down the FDA–they’ve approved 16 new drugs already this year.
Source: MDLinxCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2
The FDA has approved bempedoic acid as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia. The FDA has approved bempedoic acid as an adjunct to diet and maximally tolerated…
Source: Cardiovascular BusinessCategories: Cardiology News and JournalsTweet
Video - Steven Nissen, MD, Cleveland Clinic, explains details from the late-breaking CLEAR Outcomes trial at #ACC23 that showed bempedoic acid can be used in statin-intolerant patients #cardiotwitter #ACC23 #Nexletol #pharma #cardiology @ClevelandClinic https://t.co/mF4W4SkSkf